26th to 27th October 2017
Starting at 8am


Porto, Portugal
5* Hotel HF Ipanema Park

BioTech Pharma Summit 2017
Companion Diagnostics & Biomarkers

The BioTech Pharma Summit 2017: Companion Diagnostics & Biomarkers edition, to be held on October 26-27, 2017 in Porto, Portugal is a meeting place for leaders in the field to discuss the issues and challenges scientists and researchers face in all aspects of the biomarker and diagnostic development process from discovery to translation to commercialization.


After a sold-out first edition in March 2017, this second edition will feature on the importance of partnerships formed between and among pharma, diagnostics, and CROs to coordinate development and implementation of the drug-diagnostics pair. Talks will highlight strategy, tactics, and lessons learned as clinical trials and marketing efforts unfold.

Benefits of attending

The summit as an executive format where case study presentations and panel discussions enable an interactive exchange of ideas and experiences, you will be able to have many networking opportunities with senior peers and get post event follow up offering all documentation from the meeting and re-booking discounts.

Who should attend?

The BioTech Pharma Summit: Companion Diagnostics & Biomarkers edition is an exclusive event consisting of world-class keynote addresses and presentations designed specifically for senior level attendees from research & academic institutions, clinical research institutions and hospital laboratories as well as major pharmaceutical and biotech companies based mainly in Europe but also worldwide.

Key Speakers

Master classes from World CDx & Biomarkers experts

Jones, US

Executive Vice President, Commercial Operations at SkylineDx BV

Read his biography >>

C. Chander, US

CEO at Cellanyx Diagnostics

Read his biography >>

Ung, US

Chief Business Officer at HistoGeneX

Read his biography >>

Zhang, CN

Chairman and CEO at QIAGEN Translational Medicine

Read his biography >>

Winther, SE

SVP Business Development at ‎Immunovia

Read his biography >>

Munksted, DK

Commercial Director, Companion Diagnostics at Agilent Technologies

Read her biography >>

Hawkins, UK

Cancer Research UK Professor at University of Manchester

Read his biography >>

Whittaker, UK

Vice President Discovery Research at hVIVO

Read his biography >>

Major Conference Sections

2-days Summit full of Master-classes, Panel discussions & Interactive sessions.

9:00 am

The changing face of healthcare: dawn of individualized medicine

Dr. Harry Glorikian, US
CEO at Harry Glorikian & Advisory Board at Evidation Health

– Shift to data driven and evidence based system to support value based health and healthcare decisions
– Efficient and effective use of genetic and molecular characterization to shape the way medicine is practiced and the way drugs are approved
– Greater integration of discovery, clinical trials, and ongoing clinical care to transform evidence generation for improved healthcare decisions

11:00 am

Biomarker and CDx – the first half of Precision Medicine

Dr. Nick Zhang, CN
Chairman and CEO at QIAGEN (Suzhou) Translational Medicine Co. Ltd.

– Overview of biomarker and CDx
– Our CDx business model and case studies
– Biomarker and CDx development in China.

12:20 pm

Adoptive cell therapy for cancer using both natural and engineered T-cells

Prof. Robert Hawkins, UK
Cancer Research UK Professor at University of Manchester

3:50 pm

Personalized Oncology Solutions: Live Cell Behavior

Dr. Ashok Chander, US
CEO, Cellanyx

– Understanding the aggressiveness of cancer is the next big challenge in personalized medicine.
– Tumor heterogeneity is a major biological obstacle towards personalized medicine.
– Live Cell Phenotypic Diagnostics on primary biopsy cells is a powerful solution to understanding tumor heterogeneity.
– Emerging clinical evidence support Live Cell Phenotypic Diagnostics as an important addition to genomic technology as well as a potential new technology and class of diagnostics for personalized medicine.

9:00 am

Companion Diagnostics: a guide to cure?

Ali Ardakani, US
Managing Director at Novateur Ventures Inc.

Best practices of companion diagnostics for better drug development and successful reimbursement

– In this presentation will be looking at several best cases (and worst cases) of challenges of developing companion diagnostics and how the fait of both the drug and diagnostics changed based the clinical outcome.

11:00 am

Digital Pathology in Immuno-Oncology – A Roadmap for Clinical Development

Christopher Ung, US
Chief Business Officer at HistoGeneX

– Immuno-oncology has catalyzed histopathology applications, such as TIL location and spatial analyses, that benefit from digital pathology.
– Digital Pathology validation models are present for manufacturers and diagnostics but needed for clinical development.
– The rapid evolution of PD-L1 scoring algorithms create an acute need for pathologist training and proficiency. A well-designed training module addresses these needs

12:20 pm

The PD-L1 CDx Commercialization Journey

Susanne Munksted, DK
Commercial Director, Companion Diagnostics at Agilent Technologies

– Experiences from the world’s first PD-L1 CDx commercial launch
– Learnings from launching a complementary diagnostic, a new CDx category created by FDA
– Managing multiple PD-L1 assays and multiple partners in a competitive space
– PD-L1; a complex product lifecycle! Developing an assay in relation to global reach and new indications
– Demonstrating models and tools to sustain valuable partnerships and secure efficient CDx-Rx commercialization programs

4:20 pm

Overcoming challenges in the global commercialization of novel biomarkers

Jeffrey Jones, US
Vice President, Commercial Operations at SkylineDx

Building a comprehensive market access strategy – develop and validate your opportunity first.
Generating powerful evidence – start your publication planning early.
Communicating a compelling value proposition – leveraging an insight-driven commercialization strategy.

5:30 pm

Strategic Partnerships for CDx – Challenges and Opportunities

Henrik Winther
Senior Vice President, Precision Diagnostics at Immunovia AB

– What is required to become a successful CDx provider?
– What is required to become a successful CDx provider?
– What are the major challenges?- How could these challenges potentially be solved?
– Trusted partnership is key within Rx-CDx development


I was pleased with the quality of people represented in this event.

Javier Camposano
Managing Director - Drug Product Division - Celltrion Inc.

Thank you so much for this nice conference in Porto. It was a very nice event and the organization was very well done. Thank you for your kind hospitality in this beautiful city.

Dr. Dora Marta
Regulatory Affairs, Biotechnological Products - Gedeon Richter Plc

I enjoyed the conference, which I felt was just the right size and with the right people in it. It was a very open, interactive forum for all of us and provided us an opportunity to speak out or subject related thoughts, concerns and get perspectives from other subject experts.

Samir Kulkarni
Associate Vice President, Intas Pharmaceuticals, R&D

Thank you for organising such a well managed conference. The experience and interaction with other members was really great.

Abhishek Kulshrestha
Principal Scientific Manager R&D - Biocon

I have to congratulate EPM Group on a high quality conference. I was genuinely impressed.

Dr. Uwe Gudat
Head of Safety, Biosimilars - Merck Biosimilars

Why is this conference for you?

Networking Opportunities

Join us for the opportunity to listen to recent updates on research, share ideas with colleagues, and network with experts to advance CDx & biomarker discovery and development, the BioTech Pharma summit will assemble leading scientists, researchers, decision-makers and other players across the industry spectrum.

Wide variety of important topics

A wide variety of important topics will be covered including biomarker identification, validation, and translation strategies, bioinformatics and systems biology approaches to personalized medicine, big data analytics and management, regulatory and reimbursement trends, companion diagnostics development, and much more.

Biomarker & Companion Diagnostics specialists

The BioTech Pharma Summit has been designed by leading biomarker and companion diagnostics specialists at Roche, Novartis, Johnson & Johnson, GSK, Merck, AstraZeneca, Daiichi Sankyo, Bristol-Myers Squibb, Pfizer and many more to assist you in turning biomarker research into successful patient stratification and to deliver better, safer drugs to market with drug-diagnostic co-development.

Fresh Agenda

With all the fascinating feedback we’ve heard from our last edition, we’re putting together an agenda this year that’s packed with fresh, new insights and that addresses the most up-to-date issues and challenges in drug-diagnostic co-development with a great line-up of worldwide speakers.

Pricing & Registration

Only 150 available seats Get your Conference Tickets early.

All Delegate Fees below includes: 2 days Summit + Master Classes + Interactive Sessions; Discussion with Industry Experts; Coffee Breaks and Business Lunches. Select your ticket and fill out the information below

Fill out your information

€ 1895

Conference Package

For industry experts and solution providers

€ 599

Non-Profit or Academic Fee

Fee for members of academic, government institutions or non-profit organizations.

Sponsors & Partners

Interested in becoming a sponsor or Exhibit? Get in touch

  • Asia Research News
  • Biocompare
  • Ordem dos Farmacêuticos
  • IP Technology Exchange
  • Farma Vita Net
  • Bio-Equip
  • Tecandform
  • Lufthansa Group
  • BioPharma Asia
  • Porto and the North
  • Tecnhology Networks
  • TAP Portugal
  • Netfarma
  • Marketing Farmacêutico
  • Farma Vita
  • Chemical Search
  • ChemExec
  • Pharma Technology Focus

Location and Venue

The heart of the business district in Porto

Conference Location

5* HF Ipanema Park, Porto

Featuring an outdoor swimming pool, this 5-star hotel offers a rooftop bar with Porto and Douro River views. The HF Ipanema Park is 1 km from Serralves Museum and Garden.
Guests can enjoy their meals at the Jardim d’Inverno Restaurant or have a snack at the Twin Trees snack bar. The seaside area of Foz do Douro, with its restaurants, bars and cafes, is a 5-minute drive.
The Ribeira UNESCO World Heritage site is a 10-minute drive from the Ipanema Park, and Francisco Sá Carneiro International Airport is 12 km away.

Hotel HF Ipanema Park

Book Online
Nearby Accomodation

HF Ipanema Porto

HF Ipanema Porto offers modern rooms with LCD TV and 24-hour, secure parking. Specially furnished family rooms are also provided. Boavista Roundabout is 500 m away.
The Ipanema Porto is ideally surrounded by Porto’s commercial district, restaurants, and bars. Casa da Musica subway is nearby.

Rua Do Campo Alegre, 156/172, Lordelo do Ouro e Massarelos, 4150-169 Porto, Portugal

Book Online

Porto Palacio Congress Hotel & Spa

Located on Avenida da Boavista, Porto Palácio Congress Hotel & Spa is a 7-minute walk from Estádio do Bessa. Casa da Música and Francos metro stations are both less than a 15-minute walk from the hotel. The city centre is around 15 minutes’ drive away. Porto International Airport is 13.4 km from the hotel.

Avenida da Boavista, 1269, Lordelo do Ouro e Massarelos, 4100-130 Porto, Portugal

Book Online
Additional details

Need transport? Install the Cabify App here and use the Promo Code: BIOTECH17 Have any questions? Feel free to contact diogo.ribeiro[at]epmgroup.org or by phone: +351 915 239 640